CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Bromhexine HydrochlorideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1105 Hydroxychloroquine Sulfate + Azithromycin Wiki 1.00
drug1103 Hydroxychloroquine Sulfate Wiki 0.28

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial

This is a randomized controlled trial of the efficacy and safety evaluation of oral administration of Bromhexine hydrochloride for the prevention of SARS-CoV-2 infection and COVID-19 disease in medical personnel assisting patients with a new coronavirus disease

NCT04405999 Increased Risk of SARS-CoV-2 Infection Drug: Bromhexine Hydrochloride
MeSH:Infection Communicable Diseases

Primary Outcomes

Description: Negative PCR of SARS-CoV-2 and the absence of clinical manifestations of COVID-19 infection in individuals taking Bromhexine hydrochloride 4 weeks after randomization.

Measure: Polymerase chain reaction (PCR)

Time: 4 weeks after randomization

Secondary Outcomes

Description: Time to clinical symptoms of a respiratory infection with positive PCR SARS-CoV-2

Measure: Time to symptoms

Time: 14 days after last contact

Description: Time to detect positive SARS-CoV-2 PCR

Measure: Time to positive PCR

Time: 14 days after last contact

Description: The number of asymptomatic cases of SARS-CoV-2 infection

Measure: Number of cases

Time: 14 days after last contact

Description: The number of mild, moderate and severe forms of the disease COVID-19 with Bromhexine hydrochloride

Measure: Case severity

Time: 14 days after last contact

Description: Evaluation of adverse events

Measure: Drug tolerance

Time: 14 days after last contact


No related HPO nodes (Using clinical trials)